Advertisement

Document › Details
Max-Delbrück-Centrum für Molekulare Medizin (MDC). (12/2/19). "Press Release: Deep Learning Identifies Molecular Patterns of Cancer". Berlin.
![]() |
Organisation | Max Delbruck Center for Molecular Medicine (MDC) |
Group | Helmholtz-Gemeinschaft (HGF) (Group) | |
Organisation 2 | Bayer AG | |
Group | Bayer (Group) | |
![]() |
Product | Multi-omics Autoencoder Integration platform (maui) |
Product 2 | oncology | |
An artificial intelligence platform developed at the Max Delbrück Center for Molecular Medicine (MDC) can analyze genomic data extremely quickly, picking out key patterns to classify different types of colorectal tumors and improve the drug discovery process. The deeper analysis shows some colorectal subtypes need to be reclassified.
A new deep-learning algorithm can quickly and accurately analyze several types of genomic data from colorectal tumors for more accurate classification, which could help improve diagnosis and related treatment options, according to new research published in the journal Life Science Alliance.
Colorectal tumors are extremely varied in how they develop, require different drugs and have very different survival rates. Often, they are classified into subtypes based on analysis of gene expression levels.
“Disease is much more complex than just one gene,” said Altuna Akalin, bioinformatics scientist who leads the Bioinformatics Platform research group at MDC’s Berlin Institute of Medical Systems Biology?(BIMSB). “To appreciate the complexity, we have to use some kind of machine learning to really make use of all the data.”
To look at numerous features contained in genetic material, including gene expression, single point mutations and DNA copy-numbers, Akalin and PhD student Jonathan Ronen designed the Multi-omics Autoencoder Integration platform – “maui” for short.
How it works
Supervised machine learning typically requires human experts to label data and then train an algorithm to predict those labels. For example, to predict eye color from pictures of eyes, the researchers first feed the algorithm with pictures where eye color is labeled. The algorithm learns to identify different eye colors and can independently analyze new data.
In contrast, unsupervised machine learning does not involve training. A deep-learning algorithm is fed data without labels and sifts through it to find common patterns or representative features, which are called latent factors. For example, this kind of algorithm can process pictures of faces that are not labeled in any way, then identify key features, like eye colors, eyebrow shapes, nose shapes, smiles.
As a deep-learning platform, maui is able to analyze multiple “omics” datasets and identify the most relevant patterns or features, in this case, gene sets or pathways to colorectal cancer. Indikatoren für Darmkrebs, zu erkennen.
[Picture]
Tumor samples are clustered into the four standard colorectal subtypes based on gene expression levels. The deep-learning maui platform classified the same samples similarly, but found that subtype 2 (represented in green in figure A) might actually be two separate types (represented in green and light blue in figure B).
© Akalin Lab, MDC
Reclassifying subtypes?
maui identified patterns associated with the four established subtypes of colorectal cancer, assigning tumors to subtypes with high accuracy. It also made an interesting discovery. The platform found a pattern that suggests one subtype (CMS2) might need to be split into two separate groups. The tumors have different mechanisms and survival rates. The team suggests further investigation to verify if the subtype is unique or perhaps representative of the tumor spreading. Still, it demonstrates the power of the platform to take all the data, rather than only the known genes associated with a disease, and produce deeper insights.
“Data science can handle complex data that is hard to handle other ways and makes sense of it,” Akalin said. “You can feed it everything you have on the tumors and it finds meaningful patterns.”
Faster, better
The program was not just more accurate, it also works much faster than other machine learning algorithms – three minutes to pick out 100 patterns, compared to the other programs that took 20 minutes and 11 hours.
“It is able to learn orders of magnitude more latent factors, at a fraction of the computation time,” said Jonathan Ronen, first author of the research.
The team was actually surprised at how fast the system performs, especially because they did not have to use graphics cards that usually help speed up calculations. This shows how extremely well optimized, or efficient, the algorithm is, though they are continuing to find ways to further finetune the system.
Improving drug discovery
The team, which also included Bayer AG computational biologist Sikander Hayat, adapted their program to analyze cell lines taken from tumors and grown in labs for researching the effects of potential drug treatments. However, cell lines differ from real tumors in many ways on the molecular level. The team used maui to compare cell lines currently used for testing colorectal cancer drugs to see how closely they were related to real tumors. Nearly half of the lines were found to be more related to other cell lines than actual tumors. A handful were found to be the best lines most closely representing the different classes of CRC tumors.
While drug discovery research is moving away from cell lines, this insight could help maximize the potential impact of cell line research, and could be adapted for other types of genetic-based drug testing tools.
Google for tumors
Now that the deep-learning platform for colorectal cancer has been established, it could be used to analyze data for new patients. “Think of this like a search engine,” Akalin said.
A clinician could input the new patient’s genetic data into maui to find the closest match to quickly and accurately classify the tumor. The platform could advise what drugs have been used on the closest matching tumors and how well they worked, thus helping to predict drug responses and survival outlook.
For now, this could take place in a research setting only after doctors have tried the established protocols. It is a long road for a test or system to be approved for clinical use, Akalin said. The team is exploring the potential for commercialization with the help of the Berlin Institute of Health’s Digital Health Accelerator Program. They are also in the process of adapting maui for other types of cancers.
Text: Laura Petersen
Further information
Bioinformatics and Omics Data Science
Altuna Akalin
Dr. Altuna Akalin
Literature
Jonathan Ronen et al. (2019): „Evaluation of colorectal cancer subtypes and cell lines using deep learning“, Life Science Alliance, DOI: 10.26508/lsa.201900517
The Max Delbrück Center for Molecular Medicine (MDC)
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) was founded in Berlin in 1992. It is named for the German-American physicist Max Delbrück, who was awarded the 1969 Nobel Prize in Physiology and Medicine. The MDC's mission is to study molecular mechanisms in order to understand the origins of disease and thus be able to diagnose, prevent and fight it better and more effectively. In these efforts the MDC cooperates with the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH ) as well as with national partners such as the German Center for Cardiovascular Research and numerous international research institutions. More than 1,600 staff and guests from nearly 60 countries work at the MDC, just under 1,300 of them in scientific research. The MDC is funded by the German Federal Ministry of Education and Research (90 percent) and the State of Berlin (10 percent), and is a member of the Helmholtz Association of German Research Centers. www.mdc-berlin.de
Press contacts
Dr. Altuna Akalin
Altuna.Akalin@mdc-berlin.de
Jana Schlütter
+49(0)30-9406-2121
Jana.Schluetter@mdc-berlin.de
Record changed: 2019-12-04 |
Advertisement

More documents for Helmholtz-Gemeinschaft (HGF) (Group)
- [1] Bruker Corporation. (2/25/21). "Press Release: New Nature Communications Publication by Mann & Theis Groups Harnesses the Benefits of Large-scale Peptide Collisional Cross Section (CCS) Measurements and Deep Learning for 4D Proteomics". Munich....
- [2] Miltenyi Biotec B.V. & Co. KG. (5/28/20). "Press Release: Miltenyi Biotec Launches World’s First Fully Automated Light Sheet Microscope". Bergisch Gladbach....
- [3] Provirex Genome Editing Therapies GmbH. (4/29/20). "Press Release: Start-Up Provirex – Innovative Approach to Curing HIV Infection. Ascenion and Innovationsstarter Fonds Hamburg Acquire Equity in Hamburg Start-up". Munich....
- [4] Helmholtz-Zentrum für Infektionsforschung (HZI. (11/27/19). "Press Release: Helmholtz Gets Three more Start-ups Off the Ground. HZI Spin-off Myxobiotics Researches Active Substance against Urinary Tract Infections"....
- [5] Forschungszentrum Jülich. (5/10/19). "Press Release: Alzheimer Therapy from Jülich Passes another Important Test. Drug Candidate PRI-002 Has Successfully Completed Phase I of Clinical Research". Jülich & Vienna....
- [6] Phenex Pharmaceuticals AG. (4/5/19). "Press Release: Phenex Collaborates with Mathias Heikenwälder’s Research Group from DKFZ (German Cancer Research Center)". Ludwigshafen....
- [7] Evotec AG. (2/20/19). "Press Release: Evotec and Helmholtz Centre Joining Platforms and Forces for Novel Antibiotics". Hamburg & Braunschweig....
- [8] Medigene AG. (1/4/19). "Press Release: Medigene Licenses Co-stimulator to Enhance TCR Therapies for Solid Tumors". Planegg....
- [9] DKFZ (Deutsches Krebsforschungszentrum). (10/23/18). "Pressemittelung: Pioniergeist – Erste DKFZ-Ausgründung feiert 35-jähriges Jubiläum"....
- [10] OLS Omni Life Science GmbH & Co. KG. (10/18/18). "Press Release: CERO Is a Novel 3D Cell Cultivation System". Bremen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top